FDA-cleared profile

Rapid LVO

iSchemaView Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Notification-only triage of adult head CTA for suspected large-vessel occlusion; results do not replace diagnostic interpretation.

Clinical role
Notification tool whose algorithm analyzes images and highlights cases with suspected LVO in parallel to standard-of-care interpretation, sending notifications with compressed preview images for informational use only; it does not remove cases from the reading queue.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Compressed preview images are informational only and not for diagnostic use beyond notification; the device does not alter the original medical image and is not intended to be used as a diagnostic device. Notified clinicians must view non-compressed images on a diagnostic viewer and perform appropriate patient evaluation before care-related decisions.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Notification-only triage of adult head CTA for suspected large-vessel occlusion; results do not replace diagnostic interpretation.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: DICOM-compliant medical image data from CTA scanners through the Rapid Platform interface.
  • Who uses it?Intended users: Hospital networks and trained radiologists; notified clinicians review full images per the standard of care.
  • What does the software produce?Output: Notifications for suspected LVO findings on a server or standalone desktop application, including compressed preview images for informational triage only.
  • What is its most important limitation?Key limitation: Compressed preview images are informational only and not for diagnostic use beyond notification; the device does not alter the original medical image and is not intended to be used as a diagnostic device. Notified clinicians must view non-compressed images on a diagnostic viewer and perform appropriate patient evaluation before care-related decisions.

Clinical takeaway. Clinical role: Notification-only triage of adult head CTA for suspected large-vessel occlusion; results do not replace diagnostic interpretation.

Evidence takeaway. Evidence from the reviewed source record: Standalone performance testing reported sensitivity 0.970 (95% CI: 0.933, 0.987), specificity 0.956 (95% CI: 0.919, 0.977), and ROC AUC 0.99 (95% CI: 0.972, 0.995). Time to notification was 2.86 minutes (95% CI: 2.79, 2.92).

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Notification-only triage of adult head CTA for suspected large-vessel occlusion; results do not replace diagnostic interpretation.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Notification tool whose algorithm analyzes images and highlights cases with suspected LVO in parallel to standard-of-care interpretation, sending notifications with compressed preview images for informational use only; it does not remove cases from the reading queue.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Rapid LVO uses a software algorithm to analyze images and highlight cases with suspected LVO on a server or standalone desktop application in parallel to the ongoing standard of care image interpretation." … "The user is presented with notifications for cases with suspected LVO findings. Notifications include compressed preview images, that are meant for informational purposes only and not intended for diagnostic use beyond notification.". Read from the exact FDA decision document on 2026-11-14.

Required input
DICOM-compliant medical image data from CTA scanners through the Rapid Platform interface.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description states the DICOM-compliant CTA-scanner input path.

Output and clinician action
Notifications for suspected LVO findings on a server or standalone desktop application, including compressed preview images for informational triage only.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication describes notifications and compressed preview images; it does not support the dossier's generic qualified-user output wording.

Care setting
Patients undergoing screening for acute ischemic stroke, with head CTA images triaged for hospital networks and trained radiologists.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Rapid LVO is one input to physician diagnosis for patients undergoing screening for acute ischemic stroke." … "The device is intended to assist hospital networks and trained radiologists in workflow triage by flagging and communication of suspected positive Large Vessel Occlusion (LVO) findings in head CTA images.". Read from the exact FDA decision document on 2026-11-14.

Intended users
Hospital networks and trained radiologists; notified clinicians review full images per the standard of care.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication names hospital networks, trained radiologists, and notified clinicians.

Limitations
Compressed preview images are informational only and not for diagnostic use beyond notification; the device does not alter the original medical image and is not intended to be used as a diagnostic device. Notified clinicians must view non-compressed images on a diagnostic viewer and perform appropriate patient evaluation before care-related decisions.
  • Exact FDA submission
  • Checked 2026-09-19

These are the exact notification, diagnostic-use, image-integrity, and clinician-review boundaries in the packet.

Evidence summary
Standalone performance testing reported sensitivity 0.970 (95% CI: 0.933, 0.987), specificity 0.956 (95% CI: 0.919, 0.977), and ROC AUC 0.99 (95% CI: 0.972, 0.995). Time to notification was 2.86 minutes (95% CI: 2.79, 2.92).
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet reports these performance values and notification time; the current 95%/95% wording is not retained.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Standalone performance testing reported sensitivity 0.970 (95% CI: 0.933, 0.987), specificity 0.956 (95% CI: 0.919, 0.977), and ROC AUC 0.99 (95% CI: 0.972, 0.995). Time to notification was 2.86 minutes (95% CI: 2.79, 2.92).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet reports these performance values and notification time; the current 95%/95% wording is not retained.

Reported sensitivity
95%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

Reported specificity
95%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K200941. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM-compliant medical image data from CTA scanners through the Rapid Platform interface.

    Scope: Exact FDA submission. The exact device description states the DICOM-compliant CTA-scanner input path.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K200941: Rapid LVO

  2. Routing

    Source context, not route validation: The exact FDA package describes Rapid LVO acquiring DICOM-compliant image data from CTA scanners through the Rapid Platform, which receives DICOM images from modalities, PACS and workstations, sends DICOM images to external image consumers, and sends summary results over email and a mobile application. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "Rapid LVO acquires (DICOM compliant) medical image data from CTA scanners through the Rapid Platform interface:" … "receives DICOM images from external DICOM image providers (modalities (CT/MRI Scanners), PACS and Workstations) and sends DICOM images to external image consumers.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA K200941: Rapid LVO

  3. AI processing

    Source context, not route validation: The exact FDA package describes Rapid LVO as a module hosted by the Rapid Platform, which can be installed directly on a customer's Linux-based server or accessed online as Virtual Rapid. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "the Rapid LVO module which functions as one of many image processing modules hosted by the platform." … "Standard Rapid, which is installed directly on a customer's Linux-based server and integrated with medical image processing software such as commercial PACS.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K200941: Rapid LVO

  4. Returned objects

    Source context, not route validation: Notifications for suspected LVO findings on a server or standalone desktop application, including compressed preview images for informational triage only.

    Scope: Exact FDA submission. The exact indication describes notifications and compressed preview images; it does not support the dossier's generic qualified-user output wording.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K200941: Rapid LVO

  5. Viewer/worklist/report

    Unresolved route: Notifications for suspected LVO findings on a server or standalone desktop application, including compressed preview images for informational triage only.

    Scope: Exact FDA submission. The exact indication describes notifications and compressed preview images; it does not support the dossier's generic qualified-user output wording.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K200941: Rapid LVO

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Rapid LVO as a module hosted by the Rapid Platform, which can be installed directly on a customer's Linux-based server or accessed online as Virtual Rapid. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "the Rapid LVO module which functions as one of many image processing modules hosted by the platform." … "Standard Rapid, which is installed directly on a customer's Linux-based server and integrated with medical image processing software such as commercial PACS.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes Rapid LVO acquiring DICOM-compliant image data from CTA scanners through the Rapid Platform, which receives DICOM images from modalities, PACS and workstations, sends DICOM images to external image consumers, and sends summary results over email and a mobile application. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Rapid LVO acquires (DICOM compliant) medical image data from CTA scanners through the Rapid Platform interface:" … "receives DICOM images from external DICOM image providers (modalities (CT/MRI Scanners), PACS and Workstations) and sends DICOM images to external image consumers.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
RapidAI's current platform security and compliance one-pager states that its portfolio uses encryption at rest and in transit, role-based access control, monitoring/logging and listed HIPAA, GDPR, ISO 13485, ISO 27001, ISO 27701 and SOC 2 Type 1 claims.
  • Vendor-wide
  • Checked 2026-10-25

This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.

Monitoring
RapidAI's security and compliance one-pager (Rev 8, published by iSchemaView, Inc.) states continuous infrastructure monitoring and system telemetry to detect operational anomalies in real time, plus a formal incident response and escalation framework with defined communication protocols.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. No certificate or audit report was read; the one-pager names the RapidAI platform generally and does not scope these commitments to any specific product release; exact-release scope is not established.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Rapid LVO; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K200941
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The subject-device comparison identifies the imaging type as CT Angiography; the packet does not establish the broader CT/CTA value. Controlled directory display reconciled from exact FDA wording: CT angiography (CTA). -> CT/CTA.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication repeatedly specifies CTA head images; Brain is not the packet's wording for this field. Controlled directory display reconciled from exact FDA wording: Head. -> Brain.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-07-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
11Source classes checked
4Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 4 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 4 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor security document, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K200941 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA K200941: Rapid LVO

    U.S. Food and Drug Administration - Published 2020-07-09 - Accessed 2026-09-19

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment, integration

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rapid LVO 1.0 model card (K200941)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. RapidAI security and compliance one-pager

    RapidAI - Accessed 2026-09-08

    Scope: vendorWideSecurity, deployment, implementationCapabilities

  8. openFDA exact recall query for K200941

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  9. RapidAI security and compliance one-pager (Rev 8)

    iSchemaView, Inc. (RapidAI) - Accessed 2026-10-27

    Scope: security, monitoring

Research history

  1. K200941 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253818

Annalise Enterprise

Harrison-AI Medical Pty, Ltd.

Authorized purpose: Annalise Enterprise prioritizes and notifies trained CT clinicians of suspected acute infarct on non-contrast brain CT for adults; it is a study-level, non-localizing worklist aid and never downgrades an existing priority.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-03-03
FDA-cleared K251195

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Adult contrast-enhanced brain CT triage for suspected brain aneurysm findings at least 3.0 mm.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-01-27
FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history